<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Renin Angiotensin Aldosterone Syst</journal-id><journal-id journal-id-type="iso-abbrev">J Renin Angiotensin Aldosterone Syst</journal-id><journal-id journal-id-type="publisher-id">JRA</journal-id><journal-id journal-id-type="hwp">spjra</journal-id><journal-title-group><journal-title>Journal of the Renin-Angiotensin-Aldosterone System: JRAAS</journal-title></journal-title-group><issn pub-type="ppub">1470-3203</issn><issn pub-type="epub">1752-8976</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27317303</article-id><article-id pub-id-type="pmc">5843869</article-id><article-id pub-id-type="doi">10.1177/1470320316655005</article-id><article-id pub-id-type="publisher-id">10.1177_1470320316655005</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The effects of telmisartan on the nuclear factor of activated T lymphocytes signalling pathway in hypertensive patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Sha-Sha</given-names></name><xref ref-type="author-notes" rid="fn1-1470320316655005">*</xref></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Si-Li</given-names></name><xref ref-type="author-notes" rid="fn1-1470320316655005">*</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yuan-Ming</given-names></name><xref ref-type="corresp" rid="corresp1-1470320316655005"/></contrib></contrib-group><aff id="aff1-1470320316655005">Heart Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China</aff><author-notes><corresp id="corresp1-1470320316655005">Yuan-Ming Zhang, Heart Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China. Email: <email>13999867798@163.com</email></corresp><fn fn-type="equal" id="fn1-1470320316655005"><label>*</label><p>These authors contributed equally to this work and should be considered co-first authors.</p></fn></author-notes><pub-date pub-type="epub"><day>01</day><month>6</month><year>2016</year></pub-date><pub-date pub-type="collection"><season>Apr-Jun</season><year>2016</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>1470320316655005</elocation-id><history><date date-type="received"><day>28</day><month>1</month><year>2016</year></date><date date-type="accepted"><day>13</day><month>5</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder content-type="sage">SAGE Publications</copyright-holder><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/3.0/">http://www.creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><abstract><sec id="section1-1470320316655005"><title>Hypothesis:</title><p>Previous studies provide links between the nuclear factor of activated T lymphocytes (NFAT) signalling pathway and the development of hypertension. Our preliminary studies indicate that telmisartan can block Kv1.3 potassium channels and effectively inhibit potassium current densities, along with Kv1.3 mRNA and protein expression levels. This paper aims to investigate whether telmisartan has an inhibitory effect on the NFAT signalling pathway after activation and proliferation of peripheral blood T lymphocytes in Kazakh patients with essential hypertension (EH) from Xinjiang, China.</p></sec><sec id="section2-1470320316655005"><title>Materials and methods:</title><p>T lymphocytes were isolated using the immunomagnetic cell sorting method (MACS). The mRNA expression of NFATc1, IL-6 and TNF-&#x003b1; was measured by quantitative polymerase chain reaction (qRT-PCR) and relative protein levels were evaluated by Western blot. T cell samples from 50 hypertensive Kazakh patients from Xinjiang were randomly divided into control, telmisartan, cyclosporin A (CsA), VIVIT, and 4-aminopytidine (4-AP) groups. Peripheral blood T lymphocytes were first activated and proliferated in vitro, then incubated for 48 h under different treatment conditions before determination of protein and mRNA expression of NFATc1, IL-6, and TNF-&#x003b1; by Western blot and qRT-PCR analyses, respectively.</p></sec><sec id="section3-1470320316655005"><title>Results:</title><p>There were no significant differences in cardiovascular risk factors among the patients with samples assigned to the five groups (<italic>p</italic> &#x0003e; 0.05). Expression of NFATc1, IL-6, and TNF-&#x003b1; mRNA and protein was significantly reduced in T lymphocytes in all treatment groups (telmisartan, CsA, VIVIT, and 4-AP) compared with controls.</p></sec><sec id="section4-1470320316655005"><title>Conclusions:</title><p>Antihypertensive function and inhibitory effects of telmisartan on the T lymphocyte NFAT signalling pathway are unlikely to affect the normal immune function of hypertensive patients. Telmisartan may exert anti-inflammatory effects by inhibition of the NFAT signalling pathway in the T lymphocytes of hypertensive patients.</p></sec></abstract><kwd-group><kwd>Xinjiang Kazakh</kwd><kwd>essential hypertension</kwd><kwd>T lymphocytes</kwd><kwd>nuclear factor of activated T lymphocytes signalling pathway</kwd><kwd>telmisartan</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>cover-date</meta-name><meta-value>April-June 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="section5-1470320316655005"><title>Introduction</title><p>Essential hypertension (EH) is one of the most common cardiovascular disorders and a major risk factor for cardiovascular disease. The pathogenesis of EH includes hereditary, dietary, and psychological factors, along with neuroendocrine mechanisms. However, increasing experimental and clinical evidence indicates that inflammation also plays a critical role in the pathogenesis and development of EH.<sup><xref rid="bibr1-1470320316655005" ref-type="bibr">1</xref><xref rid="bibr2-1470320316655005" ref-type="bibr"/>&#x02013;<xref rid="bibr3-1470320316655005" ref-type="bibr">3</xref></sup> Indeed, it has been proposed that EH represents a form of chronic low-grade inflammatory disease.<sup><xref rid="bibr4-1470320316655005" ref-type="bibr">4</xref></sup> Recent studies have shown that lymphocytes, especially T lymphocytes, are involved in the occurrence and development of hypertension and vascular remodelling.<sup><xref rid="bibr5-1470320316655005" ref-type="bibr">5</xref></sup> De Miguel and co-workers<sup><xref rid="bibr6-1470320316655005" ref-type="bibr">6</xref></sup> demonstrated that inhibition of T lymphocytes lowered the level of renal angiotensin II (Ang II) and prevented occurrence of hypertension and renal damage in Dahl salt-sensitive rats. In addition, deficiency of T lymphocyte activity in mice can prevent the occurrence of hypertension,<sup><xref rid="bibr7-1470320316655005" ref-type="bibr">7</xref></sup> indicating that T lymphocytes are involved in the pathogenesis of hypertension in this animal model. Moreover, Harrison et al.<sup><xref rid="bibr8-1470320316655005" ref-type="bibr">8</xref></sup> demonstrated that T lymphocyte activation and accumulation in the adventitia and perivascular adipose tissue of both large and smaller resistance blood vessels is important in the pathogenesis and development of hypertension.</p><p>Nuclear factor of activated T lymphocytes (NFAT) is expressed in many immunocytes, including T and B lymphocytes, natural killer cells, mast cells, eosinophils, and monocytes. NFAT can selectively induce the transcription of cytokines and other immune-regulated genes, and has an essential role in the immune response process.<sup><xref rid="bibr9-1470320316655005" ref-type="bibr">9</xref></sup> The NFAT signalling pathway is an important regulator of the inflammatory response, playing a pivotal role in T lymphocyte activation and stimulating the production of a large number of inflammatory cytokines, including interleukin-6 (IL-6) and tumour necrosis factor-&#x003b1; (TNF-&#x003b1;).<sup><xref rid="bibr10-1470320316655005" ref-type="bibr">10</xref></sup> It is almost impossible to produce the cytokines required to stimulate T lymphocyte activation in the absence of sufficient NFAT.<sup><xref rid="bibr11-1470320316655005" ref-type="bibr">11</xref>,<xref rid="bibr12-1470320316655005" ref-type="bibr">12</xref></sup> In the current study, we investigated mRNA and protein expression levels of NFATc1, IL-6, and TNF-&#x003b1; in hypertensive Kazakh patients in Xinjiang, China.</p><p>Kazakh people comprise the second largest ethnic minority in the Xinjiang Uyghur Autonomous Region of China. Epidemiological studies indicate that the prevalence of EH is much higher among Xinjiang Kazakhs than other ethnic groups in Xinjiang, whereas the rates of disease awareness, cure, and control appear to be lower among Kazakhs compared with the other ethnic groups.<sup><xref rid="bibr13-1470320316655005" ref-type="bibr">13</xref></sup></p><p>Previous studies provide links between the NFAT signalling pathway and the development of hypertension. As one of the most frequently used antihypertensive drugs, the role of telmisartan in antihypertensive therapy has been intensively studied, although little is known about its effects on the NFAT signalling pathway. Our preliminary studies indicate that telmisartan can block Kv1.3 potassium channels and effectively inhibit potassium current densities, along with Kv1.3 mRNA and protein expression levels. Here, we investigated the effects of telmisartan on the NFAT signalling pathway and related molecular mechanisms after T lymphocyte activation and proliferation in the peripheral blood of Kazakh patients with EH. We used immunomagnetic cell sorting (MACS) to isolate T lymphocytes and quantitative reverse-transcribed polymerase chain reaction (qRT-PCR) and Western blot analysis to evaluate the mRNA and relative protein expression levels of NFATc1, IL-6, and TNF-&#x003b1; in hypertensive Kazakh patients. Our results suggest a new therapeutic target for the prevention and treatment of hypertension.</p></sec><sec sec-type="materials|methods" id="section6-1470320316655005"><title>Materials and methods</title><p>We chose Kazakh hypertensive patients as the main subjects of our experiments. All patients were assigned to one of five groups: (1) Controls, (2) Telmisartan, (3) CsA, (4) VIVIT, and (5) 4-aminopytidine (4-AP). There were 10 individuals in each group (five males and five females). T lymphocytes in patient peripheral blood samples were first activated and proliferated in vitro, then incubated for 48 h under different treatment conditions. Next, we used MACS to isolate T lymphocytes and qRT-PCR and Western blot analyses to measure the relative mRNA and protein expression levels of NFATc1, IL-6 and TNF-&#x003b1; in the isolated T cells. The experimental design and procedure are illustrated in <xref ref-type="fig" rid="fig1-1470320316655005">Figure 1</xref>.</p><fig id="fig1-1470320316655005" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Experimental design and procedure.</p></caption><graphic xlink:href="10.1177_1470320316655005-fig1"/></fig><sec id="section7-1470320316655005"><title>Subjects</title><p>Fifty Kazakh hypertensive patients (mean age 51.9 &#x000b1; 3.0 years) attending the hypertension clinic of the First Affiliated Hospital of Xinjiang Medical University were enrolled into the study between January and December 2014. All patients were randomised into five groups according to a computer-generated randomisation list kept by a third party. There are exactly five males and five females in each group. Their mean blood pressure was (167.2 &#x000b1; 7.0)/(102.6 &#x000b1; 5.1) mm Hg (1 mm Hg = 0.133 Kpa), without antihypertensive therapy.</p><sec id="section8-1470320316655005"><title>Inclusion criteria</title><p>The diagnostic criteria of hypertension used were those stated in the 2010 Chinese guidelines for the management of hypertension.<sup><xref rid="bibr14-1470320316655005" ref-type="bibr">14</xref></sup> Briefly, systolic blood pressure (SBP) &#x02a7e; 140 mm Hg and/or diastolic blood pressure (DBP) &#x02a7e; 90 mm Hg, without treatment with antihypertensive medication, were considered diagnostic of hypertension.</p></sec><sec id="section9-1470320316655005"><title>Exclusion criteria</title><p>Patients with 10 types of disease were excluded from our study: secondary hypertension; cerebrovascular disease; coronary heart disease, rheumatic heart disease; congenital heart disease; acute or chronic infection; autoimmune disease; important organ failure; diabetes; carotid atherosclerosis. Patients included in the study were required both to satisfy the inclusion criteria and not exhibit any of the exclusion criteria. For example, a patient with both hypertension and atherosclerosis would be excluded from our experiments.</p><p>The study was conducted according to the World Medical Association Declaration of Helsinki. All procedures were approved by the Ethics Committee of First Affiliated Hospital of Xinjiang Medical University (approval number 20131011-2) and written informed consent was provided by every subject before inclusion in the study.</p></sec></sec><sec id="section10-1470320316655005"><title>Cardiovascular risk factors data of subjects</title><p>Data for cardiovascular risk factors including age, SBP, DBP, smoking history, drinking history, body mass index (BMI), fasting blood glucose (FBG), total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL), and low-density lipoprotein cholesterol (LDL) were collected, and compared regarding whether there were significant differences among the control, telmisartan, CsA, VIVIT and 4-AP groups. Smoking was defined as currently or previously smoking. Alcohol consumption was defined as drinking at least once per week for more than half a year.<sup><xref rid="bibr15-1470320316655005" ref-type="bibr">15</xref></sup></p></sec><sec id="section11-1470320316655005"><title>Reagents</title><p>Reagent used were: human lymphocyte isolation medium (Sigma, USA); Pan T Cell Isolation Kit (Milteni, Germany); 10% foetal bovine serum (FBS) (Hyclone, New Zealand); RPMI 1640 medium (Hyclone, New Zealand); rIL-2 (Sigma, US); FITC-CD3 (Becton, Dickinson and Company, USA); Trizol (Life Technologies, USA); Reverse transcription kit (Thermo Fisher, USA); RT-PCR kit (Qiagen, Germany); RIPA Lysis Buffer (Thermo Fisher, USA); Protease inhibitor (Thermo, USA); BCA Protein Assay Kit (Thermo, USA); SDS-PAGE (BIO-RAD, USA); anti-human monoclonal antibodies against NFATc1, IL-6, TNF-&#x003b1;, and &#x003b2;-actin, and goat anti-rabbit secondary antibodies (Abcam, UK); BCIP/NBT chromogenic reagent (Invitrogen, USA); telmisartan (Boehringer-Ingelheim, Germany); CsA (Novartis, Switzerland); VIVIT (Sigma, USA); 4-AP (Sigma, USA).</p></sec><sec id="section12-1470320316655005"><title>Instruments</title><p>Instruments used were: MACS separation column, MACS separators (Milteni, Germany); flow cytometer (Beckman Coulter, USA); centrifuges (Eppendorf, Germany); 5% CO<sub>2</sub> incubator (Thermo, USA); inverted fluorescent microscope (Leica, Germany); horizontal electrophoresis apparatus (LiuYi, China); real-time fluorescence quantification PCR amplification machine (BIO-RAD, US); vertical electrophoresis apparatus (BIO-RAD, USA); Quality image analysis system (BIO-RAD, USA).</p></sec><sec id="section13-1470320316655005"><title>Experimental methods</title><sec id="section14-1470320316655005"><title>T lymphocyte isolation</title><p>Using a heparinised vacutainer, 10 ml of peripheral venous blood was collected from each subject. Peripheral blood mononuclear cells were isolated using human lymphocyte isolation medium and density gradient centrifugation. Using the Pan T Cell Isolation Kit, human T lymphocytes were isolated by depletion of non-target T lymphocytes (negative selection). Non-target T lymphocytes were labelled with a cocktail of biotin-conjugated monoclonal antibodies and the Pan T Cell MicroBead Cocktail. The magnetically labelled non-target T lymphocytes were depleted by retaining them on a MACS separation column in the magnetic field of a MACS Separator, while the unlabelled T lymphocytes passed through the column. The purity of the enriched T lymphocytes was evaluated by flow cytometry; the cells were fluorescently stained with FITC-CD3 and analysed using the MACS Quant Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence. The results showed that &#x0003e;95% of cells were T lymphocytes.</p></sec><sec id="section15-1470320316655005"><title>Cell culture</title><p>T lymphocytes were seeded in 24-well plates containing RPMI 1640 medium, 10% FBS and recombinant interleukin-2 (rIL-2), and cultured in an incubator at 37&#x000b0;C with 5% CO<sub>2</sub> for 48 h to promote T lymphocyte activation. The cultured T lymphocytes were treated as follows: telmisartan (final concentration, 100 &#x003bc;mol/l), CsA (final concentration, 10 &#x003bc;mol/l), VIVIT (final concentration, 2 &#x003bc;mol/l), 4-AP (final concentration, 3 mmol/l) and an equal amount of dimethyl sulfoxide (DMSO) solution were added to the culture media of cells from the telmisartan, CsA, VIVIT, 4-AP, and control groups, respectively. The T lymphocytes were then cultured for a further 48 h, followed by collection of T lymphocyte suspensions and division of samples into two equal parts for extraction of RNA and protein.</p></sec><sec id="section16-1470320316655005"><title>RNA extraction and qRT-PCR analysis</title><p>Total RNA was extracted from T lymphocytes using Trizol and the A260/A280 values of the resulting RNA samples were approximately 1.8&#x02013;2.0. Reverse transcription reactions were performed using 1 &#x003bc;g RNA at 42&#x000b0;C for 60 min, followed by 70&#x000b0;C for 5 min. The total volume of qRT-PCR reactions was 20 &#x003bc;l, including 10 &#x003bc;l SYBR Green PCR Master Mix (2&#x000d7;), 2 &#x003bc;l cDNA template, 0.5 &#x003bc;l each forward and reverse primers and 7 &#x003bc;l ddH2O. <italic>NFATC1</italic> (encoding NFATc1), <italic>IL6</italic> (encoding IL-6), and <italic>TNF</italic> (encoding TNF-&#x003b1;) gene sequences were obtained from GenBank. Primers were synthesised by Sangon Biotech (Shanghai). <italic>ACTB</italic> (encoding &#x003b2;-actin) was chosen as an internal reference gene (<xref ref-type="table" rid="table1-1470320316655005">Table 1</xref>). PCR and agarose gel electrophoresis were performed with cDNA templates, and standard curves were established using PCR products. The qRT-PCR reaction program was 95&#x000b0;C for 5 min, followed by 39 cycles of 95&#x000b0;C for 10s and 60&#x000b0;C for 30s. Amplification efficiencies were approximately 90&#x02013;100%. After qRT-PCR, amplicons were separated by 2% agarose gel electrophoresis. The data were analysed using the 2<sup>&#x02212;&#x00394;&#x00394;Ct</sup> method as follows: &#x00394;Ct = Ct target gene &#x02013; Ct reference gene, &#x00394;&#x00394;Ct = &#x00394;Ct experimental group &#x02013; &#x00394;Ct control group. The rate of inhibition by telmisartan was calculated as follows: Inhibitory rate % = (mRNA expression of control group &#x02013; mRNA expression of intervention group) / mRNA expression of control group &#x000d7; 100%.</p><table-wrap id="table1-1470320316655005" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Primer sequences and amplicon size.</p></caption><alternatives><graphic xlink:href="10.1177_1470320316655005-table1"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Gene</th><th align="left" rowspan="1" colspan="1">Sequences (5&#x02032;&#x02013;3&#x02032;)</th><th align="left" rowspan="1" colspan="1">Annealing temperature (&#x000b0;C)</th><th align="left" rowspan="1" colspan="1">Product length (bp)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<italic>NFATC1</italic>
</td><td rowspan="1" colspan="1">F: CAGACCATCAGGGCATCATA<break/>R: TCCAGCGTTCTCTTCATTCA</td><td rowspan="1" colspan="1">57</td><td rowspan="1" colspan="1">127</td></tr><tr><td rowspan="1" colspan="1">
<italic>IL6</italic>
</td><td rowspan="1" colspan="1">F: GGTACATCCTCGACGGCATCT<break/>R: GTGCCTCTTTGCTGCTTTCAG</td><td rowspan="1" colspan="1">59</td><td rowspan="1" colspan="1">202</td></tr><tr><td rowspan="1" colspan="1">
<italic>TNF</italic>
</td><td rowspan="1" colspan="1">F: GTGCTCCTCACCCACACCAT<break/>R: AAGACCCCTCCCAGATAGAT</td><td rowspan="1" colspan="1">58</td><td rowspan="1" colspan="1">152</td></tr><tr><td rowspan="1" colspan="1">
<italic>ACTB</italic>
</td><td rowspan="1" colspan="1">F: TGGCACCCAGCACAATGAA<break/>R: CTAAGTCATAGTCCGCCTAGAAGCA</td><td rowspan="1" colspan="1">55</td><td rowspan="1" colspan="1">186</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="section17-1470320316655005"><title>Western blots</title><p>Total proteins were extracted from T lymphocytes using RIPA lysis buffer supplemented with protease inhibitors. Protein concentration was measured by BCA protein assay and 5 &#x000b5;l loading buffer added to each sample before denaturation of proteins in a water bath at 95&#x000b0;C for 5 min and renaturation on ice for 5 min. Protein samples (20 &#x000b5;l = 30 &#x003bc;g) were added into each well of gels for SDS-PAGE. After electrophoresis, proteins were transferred to PVDF membranes and blocked with 5% skimmed milk powder for 1 h. Primary antibodies were diluted as follows: NFATc1, 1:2000; IL-6, 1:2000; TNF-&#x003b1;, 1:1000; &#x003b2;-actin, 1:5000. Blots were incubated with primary antibodies overnight at 4&#x000b0;C, with shaking. Blots were then washed with TBST, followed by incubation with alkaline phosphatase-conjugated Goat Anti-Rabbit secondary antibodies (1:2000) at room temperature for 1 h and washing with TBST. Visualisation was achieved by addition of 5 ml BCIP/NBT chromogenic reagent followed by analysis using a Quality image analysis system. The telmisartan inhibitory rate was calculated as follows: Inhibitory rate (%) = (protein expression of control group &#x02013; protein expression of interventional group) / protein expression of control group &#x000d7; 100%.</p></sec></sec><sec id="section18-1470320316655005"><title>Statistical methods</title><p>Data were statistically analysed using SPSS17.0 software and are expressed as mean &#x000b1; standard deviation (SD) or percentage (%), as appropriate. Multiple data sets were compared by one-way analysis of variance or Chi-square tests. An LSD-t test was used for comparisons between two groups. <italic>P</italic> &#x0003c; 0.05 was considered to be statistically significant.</p></sec></sec><sec sec-type="results" id="section19-1470320316655005"><title>Results</title><sec id="section20-1470320316655005"><title>Comparison of cardiovascular risk factors of individuals assigned to each of the five groups</title><p>There were no significant differences among the control, telmisartan, CsA, VIVIT, and 4-AP groups in age, SBP, DBP, smoking history, alcohol consumption history, BMI, FBG, TC, TG, HDL, or LDL (<italic>p</italic> &#x0003e; 0.05; <xref ref-type="table" rid="table2-1470320316655005">Table 2</xref>).</p><table-wrap id="table2-1470320316655005" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Comparison of cardiovascular risk factors among the control, telmisartan, CsA, VIVIT, and 4-AP groups (<italic>n</italic> = 50).</p></caption><alternatives><graphic xlink:href="10.1177_1470320316655005-table2"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Group</th><th align="left" rowspan="1" colspan="1">Control</th><th align="left" rowspan="1" colspan="1">ARB</th><th align="left" rowspan="1" colspan="1">CsA</th><th align="left" rowspan="1" colspan="1">VIVIT</th><th align="left" rowspan="1" colspan="1">4-AP</th><th align="left" rowspan="1" colspan="1"><italic>p</italic>-value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Number</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">&#x0003e; 0.05</td></tr><tr><td rowspan="1" colspan="1">(male/female)</td><td rowspan="1" colspan="1">(5/5)</td><td rowspan="1" colspan="1">(5/5)</td><td rowspan="1" colspan="1">(5/5)</td><td rowspan="1" colspan="1">(5/5)</td><td rowspan="1" colspan="1">(5/5)</td><td rowspan="1" colspan="1">&#x0003e; 0.05</td></tr><tr><td rowspan="1" colspan="1">Age (years)</td><td rowspan="1" colspan="1">52.1 &#x000b1; 3.3</td><td rowspan="1" colspan="1">52.5 &#x000b1; 2.8</td><td rowspan="1" colspan="1">50.7 &#x000b1; 3.2</td><td rowspan="1" colspan="1">51.3 &#x000b1; 2.1</td><td rowspan="1" colspan="1">53.2 &#x000b1; 2.2</td><td rowspan="1" colspan="1">&#x0003e; 0.05</td></tr><tr><td rowspan="1" colspan="1">SBP (mmHg)</td><td rowspan="1" colspan="1">168.3 &#x000b1; 7.1</td><td rowspan="1" colspan="1">166.4 &#x000b1; 5.5</td><td rowspan="1" colspan="1">167.2 &#x000b1; 7.3</td><td rowspan="1" colspan="1">169.2 &#x000b1; 6.7</td><td rowspan="1" colspan="1">165.2 &#x000b1; 5.8</td><td rowspan="1" colspan="1">&#x0003e; 0.05</td></tr><tr><td rowspan="1" colspan="1">DBP (mmHg)</td><td rowspan="1" colspan="1">101.2 &#x000b1; 3.8</td><td rowspan="1" colspan="1">104.1 &#x000b1; 6.3</td><td rowspan="1" colspan="1">101.5 &#x000b1; 5.1</td><td rowspan="1" colspan="1">103.4 &#x000b1; 3.2</td><td rowspan="1" colspan="1">102.8 &#x000b1; 4.5</td><td rowspan="1" colspan="1">&#x0003e; 0.05</td></tr><tr><td rowspan="1" colspan="1">Smoking (%)</td><td rowspan="1" colspan="1">48</td><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1">49</td><td rowspan="1" colspan="1">48</td><td rowspan="1" colspan="1">&#x0003e; 0.05</td></tr><tr><td rowspan="1" colspan="1">Drinking (%)</td><td rowspan="1" colspan="1">55</td><td rowspan="1" colspan="1">53</td><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1">52</td><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1">&#x0003e; 0.05</td></tr><tr><td rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td rowspan="1" colspan="1">26.6 &#x000b1; 2.4</td><td rowspan="1" colspan="1">26.1 &#x000b1; 3.3</td><td rowspan="1" colspan="1">25.9 &#x000b1; 1.7</td><td rowspan="1" colspan="1">26.5 &#x000b1; 2.3</td><td rowspan="1" colspan="1">26.4 &#x000b1; 1.9</td><td rowspan="1" colspan="1">&#x0003e; 0.05</td></tr><tr><td rowspan="1" colspan="1">FBG (mmol/l)</td><td rowspan="1" colspan="1">4.6 &#x000b1; 0.7</td><td rowspan="1" colspan="1">4.8 &#x000b1; 0.5</td><td rowspan="1" colspan="1">4.2 &#x000b1; 0.1</td><td rowspan="1" colspan="1">4.3 &#x000b1; 0.2</td><td rowspan="1" colspan="1">4.4 &#x000b1; 0.3</td><td rowspan="1" colspan="1">&#x0003e; 0.05</td></tr><tr><td rowspan="1" colspan="1">TC (mmol/l)</td><td rowspan="1" colspan="1">4.5 &#x000b1; 0.2</td><td rowspan="1" colspan="1">4.6 &#x000b1; 0.3</td><td rowspan="1" colspan="1">4.3 &#x000b1; 0.5</td><td rowspan="1" colspan="1">4.7 &#x000b1; 0.1</td><td rowspan="1" colspan="1">4.5 &#x000b1; 0.8</td><td rowspan="1" colspan="1">&#x0003e; 0.05</td></tr><tr><td rowspan="1" colspan="1">TG (mmol/l)</td><td rowspan="1" colspan="1">1.8 &#x000b1; 0.1</td><td rowspan="1" colspan="1">1.9 &#x000b1; 0.2</td><td rowspan="1" colspan="1">1.8 &#x000b1; 0.2</td><td rowspan="1" colspan="1">1.9 &#x000b1; 0.3</td><td rowspan="1" colspan="1">1.8 &#x000b1; 0.3</td><td rowspan="1" colspan="1">&#x0003e; 0.05</td></tr><tr><td rowspan="1" colspan="1">HDL (mmol/l)</td><td rowspan="1" colspan="1">1.3 &#x000b1; 0.1</td><td rowspan="1" colspan="1">1.2 &#x000b1; 0.1</td><td rowspan="1" colspan="1">1.2 &#x000b1; 0.2</td><td rowspan="1" colspan="1">1.3 &#x000b1; 0.2</td><td rowspan="1" colspan="1">1.3 &#x000b1; 0.3</td><td rowspan="1" colspan="1">&#x0003e; 0.05</td></tr><tr><td rowspan="1" colspan="1">LDL (mmol/l)</td><td rowspan="1" colspan="1">3.3 &#x000b1; 0.2</td><td rowspan="1" colspan="1">3.2 &#x000b1; 0.4</td><td rowspan="1" colspan="1">3.4 &#x000b1; 0.5</td><td rowspan="1" colspan="1">3.3 &#x000b1; 0.7</td><td rowspan="1" colspan="1">3.2 &#x000b1; 0.3</td><td rowspan="1" colspan="1">&#x0003e; 0.05</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-1470320316655005"><p>SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; FBG: fasting blood glucose; TC: total cholesterol; TG: triglyceride; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section21-1470320316655005"><title>Effect of telmisartan, CsA, VIVIT, and 4-AP on NFATC1, IL6, and TNF-&#x003b1; mRNA expression in T lymphocytes</title><p>The mRNA expression of <italic>NFATC1, IL6</italic>, and <italic>TNF</italic> in peripheral blood T lymphocytes was examined in the five experimental groups. Amplicons of the correct size were observed after agarose gel electrophoresis. The results demonstrated significantly decreased mRNA expression levels of all three genes in T lymphocytes from the telmisartan, CsA, VIVIT, and 4-AP groups compared with controls (<italic>p</italic> &#x0003c; 0.05). In addition, levels of all three genes were lower in the CsA, VIVIT, and 4-AP groups compared with those in the telmisartan group (<italic>p</italic> &#x0003c; 0.05). There was no statistically significant difference in expression of the three genes among the CsA, VIVIT, and 4-AP groups (<italic>p</italic> &#x0003e; 0.05) (<xref ref-type="fig" rid="fig1-1470320316655005">Figure 2</xref>). Telmisartan inhibited mRNA expression of <italic>NFATC1, IL6</italic>, and <italic>TNF</italic> in T lymphocytes by 50.0%, 73.5%, and 50.0%, respectively.</p><fig id="fig2-1470320316655005" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>mRNA expression of (A) <italic>NFATC1</italic>, (B) <italic>IL6</italic>, and (C) <italic>TNF</italic>, relative to <italic>ACTB</italic> in samples extracted from activated peripheral blood T lymphocytes from Xinjiang Kazakh patients with EH, determined by qRT-PCR. Cells were treated with DMSO (control); telmisartan (100 &#x003bc;mol/l); cyclosporin A (10 &#x003bc;mol/l); VIVIT (2 &#x003bc;mol/l); and 4-AP (3 mmol/l). <italic>N</italic> = 10 in each treatment group.</p></caption><graphic xlink:href="10.1177_1470320316655005-fig2"/></fig></sec><sec id="section22-1470320316655005"><title>Effect of telmisartan, CsA, VIVIT, and 4-AP on NFATc1, IL-6, and TNF-&#x003b1; protein expression in T lymphocytes</title><p>Western blot analysis revealed that NFATc1, IL-6, and TNF-&#x003b1; proteins were expressed in peripheral blood T lymphocytes of all five groups. Levels of NFATc1, IL-6, and TNF-&#x003b1; were significantly lower in T lymphocytes from the telmisartan, CsA, VIVIT, and 4-AP groups compared with those in the control group (<italic>p</italic> &#x0003c; 0.05). In addition, expression levels of all three proteins were significantly decreased in the CsA, VIVIT, and 4-AP groups compared with that in the telmisartan group (<italic>p</italic> &#x0003c; 0.05). There were no statistically significant differences among the CsA, VIVIT, and 4-AP groups (<italic>p</italic> &#x0003e; 0.05) (<xref ref-type="fig" rid="fig2-1470320316655005">Figures 3</xref> and <xref ref-type="fig" rid="fig3-1470320316655005">4</xref>). Telmisartan inhibited protein expression of NFATc1, IL-6, and TNF-&#x003b1; in T lymphocytes by 47.5%, 47.9%, and 21.1%, respectively.</p><fig id="fig3-1470320316655005" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Representative Western blots of protein samples extracted from activated peripheral blood T lymphocytes from Xinjiang Kazakh patients with EH. Cells were treated with: 1, DMSO (Control); 2, telmisartan (100 &#x003bc;mol/l); 3, cyclosporin A (10 &#x003bc;mol/l); 4, VIVIT (2 &#x003bc;mol/l); and 5, 4-AP (3 mmol/l). Blots were probed with antibodies against NFATc1, IL-6, TNF-&#x003b1;, and &#x003b2; actin.</p></caption><graphic xlink:href="10.1177_1470320316655005-fig3"/></fig><fig id="fig4-1470320316655005" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Protein expression of (A) NFATc1, (B) IL-6, and (C) TNF-&#x003b1;, relative to &#x003b2; actin in samples extracted from activated peripheral blood T lymphocytes from Xinjiang Kazakh patients with EH, determined from Western blots. Cells were treated with DMSO (control); telmisartan (100 &#x003bc;mol/l); cyclosporin A (10 &#x003bc;mol/l); VIVIT (2 &#x003bc;mol/l); and 4-AP (3 mmol/l). <italic>N</italic> = 10 in each treatment group.</p></caption><graphic xlink:href="10.1177_1470320316655005-fig4"/></fig></sec></sec><sec sec-type="discussion" id="section23-1470320316655005"><title>Discussion</title><p>Based on the above results, we conclude that the inhibitory effect of telmisartan on the NFAT signalling pathway and related molecules, including IL-6 and TNF-&#x003b1;, in T lymphocytes from hypertensive patients was less than that of CsA, VIVIT, and 4-AP, indicating that the antihypertensive function and inhibitory effects of telmisartan on the T lymphocyte NFAT signalling pathway are unlikely to affect the normal immune function of hypertensive patients.</p><p>Several studies have provided evidence that activation of the NFAT signalling pathway is dependent on intracellular Ca<sup>2+</sup> concentration. NFAT, either alone or together with various other nuclear transcription factors (AP1, GATA, FOXP3), can induce transcription of target genes, including <italic>IL6, IL2, IL4</italic>, and <italic>TNF</italic>, leading to their specific expression.<sup><xref rid="bibr16-1470320316655005" ref-type="bibr">16</xref><xref rid="bibr17-1470320316655005" ref-type="bibr"/><xref rid="bibr18-1470320316655005" ref-type="bibr"/><xref rid="bibr19-1470320316655005" ref-type="bibr"/><xref rid="bibr20-1470320316655005" ref-type="bibr"/><xref rid="bibr21-1470320316655005" ref-type="bibr"/><xref rid="bibr22-1470320316655005" ref-type="bibr"/><xref rid="bibr23-1470320316655005" ref-type="bibr"/>&#x02013;<xref rid="bibr24-1470320316655005" ref-type="bibr">24</xref></sup> Activation of the NFAT signalling pathway mediates T lymphocyte proliferation and release of inflammatory cytokines to promote the development of hypertension. A large amount of IL-6 is released into the extracellular fluid on T lymphocyte activation, influencing lymphocyte differentiation and migration, activating the NFAT signalling pathway, and leading to further lymphocyte activation. Activated lymphocytes generate additional inflammatory cytokines, such as IL-17, and promote Ang II release. This inflammatory environment, including IL-6, IL-17, and Ang II, along with other cytokines, promotes sodium retention in the renal system and blood vessels, leading to vasoconstriction and vascular remodelling, and ultimately hypertension.<sup><xref rid="bibr25-1470320316655005" ref-type="bibr">25</xref></sup></p><p>Data from our preliminary studies<sup><xref rid="bibr26-1470320316655005" ref-type="bibr">26</xref>,<xref rid="bibr27-1470320316655005" ref-type="bibr">27</xref></sup> indicate that the expression and activation of Kv1.3 potassium channels were increased in peripheral blood T lymphocytes from Xinjiang Kazakh hypertensive patients compared with that in healthy subjects. We also found that the angiotensin receptor blocker, telmisartan, which is widely used to treat hypertension, can block Kv1.3 potassium channels in lymphocytes of spontaneously hypertensive rats in a concentration-dependent manner,<sup><xref rid="bibr28-1470320316655005" ref-type="bibr">28</xref></sup> consistent with other studies.<sup><xref rid="bibr29-1470320316655005" ref-type="bibr">29</xref><xref rid="bibr30-1470320316655005" ref-type="bibr"/><xref rid="bibr31-1470320316655005" ref-type="bibr"/>&#x02013;<xref rid="bibr32-1470320316655005" ref-type="bibr">32</xref></sup> In addition, telmisartan effectively inhibits potassium current densities, along with Kv1.3 mRNA and protein expression levels in peripheral blood T lymphocytes of Kazakh patients with EH in a time-dependent manner.<sup><xref rid="bibr33-1470320316655005" ref-type="bibr">33</xref></sup> Hence, angiotensin receptor blockers, including telmisartan, have the potential to exert potent anti-inflammatory effects by blocking Kv1.3 potassium channels on T lymphocytes. Activated T lymphocyte potassium channels can enhance potassium ion efflux, which increases the electric potential gradient on both sides of the cytomembrane, generating hyperpolarisation to promote calcium ion influx, causing a transient increase in calcium concentration and subsequent Calcineurin (CaN)-mediated dephosphorylation of NFAT and activation of the NFAT signalling pathway. In this experiment, we found that telmisartan can effectively inhibit mRNA and protein expression of NFATc1, IL-6, and TNF-&#x003b1; in peripheral blood T lymphocytes of hypertensive Kazakh patients. These data provide an important link between the NFAT signalling pathway and the Kv1.3 potassium channel.</p><p>Nataraj et al.<sup><xref rid="bibr34-1470320316655005" ref-type="bibr">34</xref></sup> demonstrated that the angiotensin type I receptor (AT1R) is strongly expressed on T lymphocytes. AT1R can increase intracellular Ca<sup>2+</sup> concentration by activating T lymphocyte potassium channels and thus trigger Ca<sup>2+</sup> mediated activation of the NFAT signalling pathway, leading to T lymphocyte activation and proliferation. Telmisartan can inhibit T lymphocyte potassium channels, resulting in decreased influx of extracellular Ca<sup>2+</sup> into the cytoplasm and a consequent decrease in intracellular Ca<sup>2+</sup> concentration and inhibition of the NFAT signalling pathway. This leads to strong suppression of activation and proliferation of T lymphocytes, promoting an anti-inflammatory environment. Therefore, we used the angiotensin blocker, telmisartan, to inhibit the NFAT signalling pathway in T lymphocytes and obtained preliminarily data indicating that telmisartan can have an anti-inflammatory effect by inhibiting the NFAT signalling pathway through blocking T lymphocyte Kv1.3 potassium channels. We conclude that increased expression of potassium channels on T lymphocytes enhances potassium ion efflux, and that the increased electric potential gradient on both sides of the cytomembrane generates hyperpolarisation to promote calcium ion influx, cause a transient increase in calcium concentration, and subsequent CaN-mediated dephosphorylation of NFAT and activation of the NFAT signalling pathway.</p><p>Similarly, both cyclosporin A (CsA) and VIVIT are immunosuppressants; CaN and NFAT are their respective target enzymes. These two inhibitors can block the NFAT signalling pathway by suppressing the activities of CsA and VIVIT, and consequently nuclear translocation of transcription factors and activation of some inflammatory cytokines are also inhibited, preventing activation and proliferation of T lymphocytes.<sup><xref rid="bibr12-1470320316655005" ref-type="bibr">12</xref></sup> 4-aminopytidine (4-AP) is a blocker of the Kv1.3 potassium channel, and its action leads to strong suppression of transmembrane potential formation and suppression of extracellular Ca<sup>2+</sup> influx to the cytoplasm, with an ultimately anti-inflammatory effect.</p><p>We investigated the effects of telmisartan on the NFAT signalling pathway and related molecular expression in peripheral blood T lymphocytes of Kazakh patients with EH and found that telmisartan could effectively inhibit NFATc1, IL-6, and TNF-&#x003b1; mRNA and protein expression. However, the specific mechanism by which this occurs is not entirely clear and requires further study.</p><p>Taken together, our results indicate that telmisartan can not only lower blood pressure directly by blocking the renin&#x02013;angiotensin&#x02013;aldosterone system, but also regulate hypertensive inflammation indirectly by inhibiting the NFAT signalling pathway of T lymphocytes. It is conceivable that specific targeted inhibition of related signalling pathways in T lymphocytes could be used to treat hypertension in humans; however, additional studies are needed in this area.</p></sec></body><back><ack><p>Thanks are due to TX Ding, CL Lv and Z Han for assistance with the experiments and to JL Huang and CX Lv for valuable discussion.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Declaration of conflicting interests:</bold> The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Natural Science Foundation of China (grant number 81160039).</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-1470320316655005"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mangin</surname><given-names>M</given-names></name></person-group>
<article-title>Hypertension and inflammation: the infection connection</article-title>. <source>J Am Soc Hypertens</source>
<year>2014</year>; <volume>8</volume>(<issue>suppl 1</issue>): <fpage>e7</fpage>.</mixed-citation></ref><ref id="bibr2-1470320316655005"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Harrison</surname><given-names>DG</given-names></name><name><surname>Guzik</surname><given-names>TG</given-names></name><name><surname>Lob</surname><given-names>HE</given-names></name><etal/></person-group>
<article-title>Inflammation, immunity, and hypertension</article-title>. <source>Hypertension</source>
<year>2011</year>; <volume>57</volume>: <fpage>132</fpage>&#x02013;<lpage>140</lpage>.<pub-id pub-id-type="pmid">21149826</pub-id></mixed-citation></ref><ref id="bibr3-1470320316655005"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miguel</surname><given-names>CD</given-names></name><name><surname>Rudemiller</surname><given-names>NP</given-names></name><name><surname>Abais</surname><given-names>JM</given-names></name><etal/></person-group>
<article-title>Inflammation and hypertension: New understandings and potential therapeutic targets</article-title>. <source>Curr Hypertens Rep</source>
<year>2015</year>; <volume>17</volume>: <fpage>1</fpage>&#x02013;<lpage>10</lpage>.</mixed-citation></ref><ref id="bibr4-1470320316655005"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dinh</surname><given-names>QN</given-names></name><name><surname>Drummond</surname><given-names>GR</given-names></name><name><surname>Sobey</surname><given-names>CG</given-names></name><etal/></person-group>
<article-title>Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension</article-title>. <source>Biomed Res Int</source>
<year>2014</year>; <volume>7</volume>: <fpage>871</fpage>&#x02013;<lpage>882</lpage>.</mixed-citation></ref><ref id="bibr5-1470320316655005"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Crowley</surname><given-names>SD</given-names></name></person-group>
<article-title>Role of T lymphocytes in hypertension</article-title>. <source>Curr Opin Pharmacol</source>
<year>2015</year>; <volume>21</volume>: <fpage>14</fpage>&#x02013;<lpage>19</lpage>.<pub-id pub-id-type="pmid">25523165</pub-id></mixed-citation></ref><ref id="bibr6-1470320316655005"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Miguel</surname><given-names>C</given-names></name><name><surname>Guo</surname><given-names>C</given-names></name><name><surname>Lund</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Infiltrating T lymphocytes in the kidney increase oxidative stress and participate in the development of hypertension and renal disease</article-title>. <source>Am J Physiol Renal Physiol</source>
<year>2011</year>; <volume>300</volume>: <fpage>F734</fpage>&#x02013;<lpage>F742</lpage>.<pub-id pub-id-type="pmid">21159736</pub-id></mixed-citation></ref><ref id="bibr7-1470320316655005"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Crowley</surname><given-names>SD</given-names></name><name><surname>Song</surname><given-names>YS</given-names></name><name><surname>Lin</surname><given-names>EE</given-names></name><etal/></person-group>
<article-title>Lymphocyte responses exacerbate angiotensin II-dependent hypertension</article-title>. <source>Am J Physiol Regulatory Integrative Comp Physiol</source>
<year>2010</year>; <volume>298</volume>: <fpage>R1089</fpage>&#x02013;<lpage>R1097</lpage>.</mixed-citation></ref><ref id="bibr8-1470320316655005"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Harrison</surname><given-names>DG</given-names></name><name><surname>Vinh</surname><given-names>A</given-names></name><name><surname>Lob</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Role of the adaptive immune system in hypertension</article-title>. <source>Curr Opin Pharmacol</source>
<year>2010</year>; <volume>10</volume>: <fpage>203</fpage>&#x02013;<lpage>207</lpage>.<pub-id pub-id-type="pmid">20167535</pub-id></mixed-citation></ref><ref id="bibr9-1470320316655005"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vandewalle</surname><given-names>A</given-names></name><name><surname>Tourneur</surname><given-names>E</given-names></name><name><surname>Bens</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Calcineurin/NFAT signaling and innate host defence: A role for NOD1-mediated phagocytic functions</article-title>. <source>Cell Commun Signal</source>
<year>2014</year>; <volume>12</volume>: <fpage>1</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="pmid">24383791</pub-id></mixed-citation></ref><ref id="bibr10-1470320316655005"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ariel</surname><given-names>Q</given-names></name><name><surname>D&#x000e9;sir&#x000e9;e</surname><given-names>G</given-names></name><name><surname>Schwarz</surname><given-names>EC</given-names></name><etal/></person-group>
<article-title>Calcium-dependent activation of T-lymphocytes</article-title>. <source>Pflugers Arch</source>
<year>2015</year>; <volume>450</volume>: <fpage>1</fpage>&#x02013;<lpage>12</lpage>.</mixed-citation></ref><ref id="bibr11-1470320316655005"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nieves</surname><given-names>NS</given-names></name><name><surname>Puga</surname><given-names>I</given-names></name><name><surname>Macian</surname><given-names>F</given-names></name></person-group>
<article-title>NFAT family of transcription factors</article-title>. <source>Biophys J</source>
<year>2015</year>; <volume>108</volume>: <fpage>846</fpage>&#x02013;<lpage>850</lpage>.</mixed-citation></ref><ref id="bibr12-1470320316655005"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martinez</surname><given-names>GJ</given-names></name><name><surname>Pereira</surname><given-names>RM</given-names></name><name><surname>Kim</surname><given-names>EY</given-names></name><etal/></person-group>
<article-title>The transcription factor NFAT promotes exhaustion of activated CD8(+) T cells</article-title>. <source>Immunity</source>
<year>2015</year>; <volume>42</volume>: <fpage>265</fpage>&#x02013;<lpage>278</lpage>.<pub-id pub-id-type="pmid">25680272</pub-id></mixed-citation></ref><ref id="bibr13-1470320316655005"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Ma</surname><given-names>YT</given-names></name><name><surname>Yang</surname><given-names>YN</given-names></name><etal/></person-group>
<article-title>Current status of primary hypertension in Xinjiang: An epidemiological study of Han, Uygur and Hazakh populations</article-title>. <source>Zhonghua Yi Xue Za Zhi</source>
<year>2010</year>; <volume>90</volume>: <fpage>3259</fpage>&#x02013;<lpage>3263</lpage>.<pub-id pub-id-type="pmid">21223782</pub-id></mixed-citation></ref><ref id="bibr14-1470320316655005"><label>14</label><mixed-citation publication-type="journal">
<collab>Writing group of 2010 Chinese guidelines for the management of hypertension</collab>. <article-title>2010 Chinese guidelines for the management of hypertension</article-title>. <source>Zhonghua gao xue ya za zhi</source>
<year>2011</year>; <volume>19</volume>: <fpage>701</fpage>&#x02013;<lpage>743</lpage>.</mixed-citation></ref><ref id="bibr15-1470320316655005"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Prevalence and determinants of prehypertension in a Chinese population of 34&#x02013;45 years old</article-title>. <source>Zhonghua gao xue ya za zhi</source>
<year>2010</year>; <volume>18</volume>: <fpage>187</fpage>&#x02013;<lpage>192</lpage>.</mixed-citation></ref><ref id="bibr16-1470320316655005"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mortlock</surname><given-names>SA</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Williamson</surname><given-names>P</given-names></name></person-group>
<article-title>T-cell activation and early gene response in dogs</article-title>. <source>Plos One</source>
<year>2015</year>; <volume>10</volume>: <fpage>295</fpage>&#x02013;<lpage>298</lpage>.</mixed-citation></ref><ref id="bibr17-1470320316655005"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wong</surname><given-names>WF</given-names></name><name><surname>Looi</surname><given-names>CY</given-names></name><name><surname>Kon</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>T- cell receptor signaling induces proximal Runx1 transactivation via a calcineurin-NFAT pathway</article-title>. <source>Eur J Immunol</source>
<year>2014</year>; <volume>44</volume>: <fpage>894</fpage>&#x02013;<lpage>904</lpage>.<pub-id pub-id-type="pmid">24310293</pub-id></mixed-citation></ref><ref id="bibr18-1470320316655005"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tran</surname><given-names>QC</given-names></name><name><surname>Leboucher</surname><given-names>S</given-names></name><name><surname>Passaro</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>The calcineurin/NFAT pathway is activated in diagnostic breast cancer cases and is essential to survival and metastasis of mammary cancer cells</article-title>. <source>Cell Death Dis</source>
<year>2015</year>; <volume>6</volume>: <fpage>e1658</fpage>.<pub-id pub-id-type="pmid">25719243</pub-id></mixed-citation></ref><ref id="bibr19-1470320316655005"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Walther</surname><given-names>S</given-names></name><name><surname>Awad</surname><given-names>S</given-names></name><name><surname>Lonchyna</surname><given-names>VA</given-names></name><etal/></person-group>
<article-title>NFAT transcription factor regulation by urocortin II in cardiac myocytes and heart failure</article-title>. <source>Am J Physiol Heart C</source>
<year>2014</year>; <volume>306</volume>: <fpage>H856</fpage>&#x02013;<lpage>H866</lpage>.</mixed-citation></ref><ref id="bibr20-1470320316655005"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>K&#x000fc;per</surname><given-names>C</given-names></name><name><surname>Beck</surname><given-names>FX</given-names></name><name><surname>Neuhofer</surname><given-names>W</given-names></name></person-group>
<article-title>NFAT5-mediated expression of S100A4 contributes to proliferation and migration of renal carcinoma cells</article-title>. <source>Front Physiol</source>
<year>2014</year>; <volume>5</volume>: <fpage>293</fpage>&#x02013;<lpage>306</lpage>.<pub-id pub-id-type="pmid">25152734</pub-id></mixed-citation></ref><ref id="bibr21-1470320316655005"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>MC</given-names></name><name><surname>Nofit</surname><given-names>BA</given-names></name><name><surname>Kathleen</surname><given-names>MG</given-names></name><etal/></person-group>
<article-title>NFAT targets signaling molecules to gene promoters in pancreatic &#x003b2;-cells</article-title>. <source>Mol Endocrinol</source>
<year>2015</year>; <volume>29</volume>: <fpage>274</fpage>&#x02013;<lpage>288</lpage>.<pub-id pub-id-type="pmid">25496032</pub-id></mixed-citation></ref><ref id="bibr22-1470320316655005"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ming</surname><given-names>NC</given-names></name><name><surname>Garima</surname><given-names>S</given-names></name><name><surname>Alexander</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>NFATc1 links EGFR signaling to induction of Sox9 transcription and Acinar-Ductal transdifferentiation in the pancreas</article-title>. <source>Gastroenterology</source>
<year>2015</year>; <volume>54</volume>: <fpage>60</fpage>&#x02013;<lpage>68</lpage>.</mixed-citation></ref><ref id="bibr23-1470320316655005"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Igor</surname><given-names>I</given-names></name><name><surname>Yuejin</surname><given-names>W</given-names></name><name><surname>Colbran</surname><given-names>RJ</given-names></name><etal/></person-group>
<article-title>Retraction calmodulin kinase determines calcium-dependent facilitation of L-type calcium channels</article-title>. <source>Nat Cell Biol</source>
<year>2015</year>; <volume>17</volume>: <fpage>551</fpage>&#x02013;<lpage>553</lpage>.</mixed-citation></ref><ref id="bibr24-1470320316655005"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Murphy</surname><given-names>J</given-names></name><name><surname>Sanderson</surname><given-names>J</given-names></name><name><surname>Gorski</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>AKAP-anchored PKA maintains neuronal L-type calcium channel activity and NFAT transcriptional signaling</article-title>. <source>Cell Rep</source>
<year>2014</year>; <volume>7</volume>: <fpage>1577</fpage>&#x02013;<lpage>1588</lpage>.<pub-id pub-id-type="pmid">24835999</pub-id></mixed-citation></ref><ref id="bibr25-1470320316655005"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Harrison</surname><given-names>DG</given-names></name><name><surname>Marvar</surname><given-names>PJ</given-names></name><name><surname>Titze</surname><given-names>JM</given-names></name></person-group>
<article-title>Vascular inflammatory cells in hypertension</article-title>. <source>Front Physiol</source>
<year>2012</year>; <volume>3</volume>: <fpage>128</fpage>&#x02013;<lpage>137</lpage>.<pub-id pub-id-type="pmid">22586409</pub-id></mixed-citation></ref><ref id="bibr26-1470320316655005"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>QB</given-names></name><name><surname>Zhang</surname><given-names>YM</given-names></name><name><surname>Cheng</surname><given-names>LF</given-names></name><etal/></person-group>
<article-title>Voltage-dependent potassium channel and calcium-activated potassium channel current changes of peripheral blood T-lymphocytes from hypertensive patients in Xinjiang Kazakh</article-title>. <source>Zhonghua Xin Xue Guan Bing Za Zhi</source>
<year>2013</year>; <volume>41</volume>: <fpage>1020</fpage>&#x02013;<lpage>1024</lpage>.<pub-id pub-id-type="pmid">24524604</pub-id></mixed-citation></ref><ref id="bibr27-1470320316655005"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dai</surname><given-names>XJ</given-names></name><name><surname>Zhang</surname><given-names>YM</given-names></name><name><surname>Hou</surname><given-names>XL</given-names></name><etal/></person-group>
<article-title>The expression of peripheral blood T lymphocytes Kv1.3 channel in patients with hypertension in Xinjiang Kazakh</article-title>. <source>Zhonghua gao xue ya za zhi</source>
<year>2012</year>; <volume>20</volume>: <fpage>175</fpage>&#x02013;<lpage>178</lpage>.</mixed-citation></ref><ref id="bibr28-1470320316655005"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>YM</given-names></name><name><surname>Ma</surname><given-names>KT</given-names></name><etal/></person-group>
<article-title>Effects of telmisartan on voltage dependent potassium channel expression in lymphocyte from spontaneously hypertensive rat</article-title>. <source>Zhonghua gao xue ya za zhi</source>
<year>2010</year>; <volume>07</volume>: <fpage>639</fpage>&#x02013;<lpage>642</lpage>.</mixed-citation></ref><ref id="bibr29-1470320316655005"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Manabe</surname><given-names>S</given-names></name><name><surname>Okura</surname><given-names>T</given-names></name><name><surname>Fukuoka</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension</article-title>. <source>J Cardiovasc Pharmacol</source>
<year>2005</year>; <volume>46</volume>: <fpage>735</fpage>&#x02013;<lpage>739</lpage>.<pub-id pub-id-type="pmid">16306795</pub-id></mixed-citation></ref><ref id="bibr30-1470320316655005"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schieffer</surname><given-names>B</given-names></name><name><surname>B&#x000fc;nte</surname><given-names>C</given-names></name><name><surname>Witte</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease</article-title>. <source>J Am Coll Cardiol</source>
<year>2004</year>; <volume>44</volume>: <fpage>362</fpage>&#x02013;<lpage>368</lpage>.<pub-id pub-id-type="pmid">15261932</pub-id></mixed-citation></ref><ref id="bibr31-1470320316655005"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sanz-Rosa</surname><given-names>D</given-names></name><name><surname>Oubina</surname><given-names>MP</given-names></name><name><surname>Cediel</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: Role of NF-kappaB/IkappaB system</article-title>. <source>Am J Physiol Heart Circ Physiol</source>
<year>2005</year>; <volume>288</volume>: <fpage>H111</fpage>&#x02013;<lpage>H115</lpage>.<pub-id pub-id-type="pmid">15308481</pub-id></mixed-citation></ref><ref id="bibr32-1470320316655005"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fliser</surname><given-names>D</given-names></name><name><surname>Buchholz</surname><given-names>KH</given-names></name></person-group>
<article-title>Antiinflammation effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation</article-title>. <source>Circulation</source>
<year>2004</year>; <volume>110</volume>: <fpage>1103</fpage>&#x02013;<lpage>1107</lpage>.<pub-id pub-id-type="pmid">15313950</pub-id></mixed-citation></ref><ref id="bibr33-1470320316655005"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>QB</given-names></name><name><surname>Gou</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>YM</given-names></name><etal/></person-group>
<article-title>The inhibitory effect of telmisartan on voltage-dependant potassium channel expression in peripheral blood T lymphocytes of patients with hypertension</article-title>. <source>Zhonghua gao xue ya za zhi</source>
<year>2014</year>; <volume>22</volume>: <fpage>1162</fpage>&#x02013;<lpage>1166</lpage>.</mixed-citation></ref><ref id="bibr34-1470320316655005"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nataraj</surname><given-names>C</given-names></name><name><surname>Oliverio</surname><given-names>MI</given-names></name><name><surname>Mannon</surname><given-names>RB</given-names></name><etal/></person-group>
<article-title>Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway</article-title>. <source>J Clin Invest</source>
<year>1999</year>: <volume>104</volume>: <fpage>1693</fpage>&#x02013;<lpage>1701</lpage>.<pub-id pub-id-type="pmid">10606623</pub-id></mixed-citation></ref></ref-list></back></article>